P-0107 - Prognostic factors in elderly patients with advanced pancreatic cancer treated with gemcitabine: a retrospective analysis of multicenter study

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Pancreatic Cancer
Presenter Ali Inal
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors A. Inal1, A. Isıkdogan2, T. Kos F.3, E. Algin4, R. Yıldız4, V. Berk5, T. Unek6, C. Dılsen7, K. Helvacı8, C. Geredeli9, F. Dane10, O. Balakan11, A. Durnalı12, H. Harputoglu13, S. Buyukberber4
  • 1Mersin Government Hospital, Department of Medical Oncology, Mersin/TR
  • 2Dicle University, Department of Medical Oncology, Diyarbakir/TR
  • 3Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara/TR
  • 4Gazi University, Department of Medical Oncology, Ankara/TR
  • 5Erciyes University, Department of Medical Oncology, Kayseri/TR
  • 6Dokuz Eylul University, Department of Medical Oncology, Izmir/TR
  • 7Yildirim Beyazit Education and Research Hospital, Department of Medical Oncology, Ankara/TR
  • 8Dr. Abdurrahman Yurtaslan Education and Research Hospital, Ankara/TR
  • 9Secuk University, Meram Medical Faculty, Department of Medical Oncology, Konya/TR
  • 10Marmara University School of Medicine, Division of Medical Oncology, Istanbul/TR
  • 11Gaziantep University, Department of Medical Oncology, Gaziantep/TR
  • 12Dr. Abdurrahman Yurtaslan Education and Research Hospital, Department of Medical Oncology, Ankara/TR
  • 13Inonu University, Department of Medical Oncology, Malatya/TR

Abstract

Introduction

At the time of diagnosis, the majority of patients with pancreatic cancer are diagnosed in advanced diseaseease. Pancreatic cancer in older individuals is frequently undertreated. Patients eligible for gemcitabine based chemotherapy should be selected carefully. The aim of this retrospective multicenter -center study was to evaluate prognostic factors for overall survival (OS) in elderly (≥65 years) patients with pancreatic cancer who received first-line palliative gemcitabine-based chemotherapy.

Methods

We retrospectively reviewed 106 advanced pancreatic cancer patients who were treated with gemcitabine chemotherapy as first-line chemotherapy. Nine potential prognostic variables were chosen for analysis. The variables were divided into two categories: gender (male or female), ECOG performance status (0-1, 2-3), location of primary tumor (head or body–tail), grade (well, poor or moderate), serum carcinoembryonic antigen (CEA) level (<10 or ≥10 ng/ml) and serum carbohydrate antigen 19-9 (CA19-9) level (<1000 or ≥1000 U/ml), presence of diabetes mellitus at diagnosis, presence of cholestasis at diagnosis, and weight loss. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS. Univariate and multivariate statistical methods were used to determine prognostic factors.

Results

Among the 9 variables of univariate analysis, 2 were identified to have prognostic significance: weight loss (p = 0.03) and serum carcinoembryonic antigen (CEA) level (p = 0.004) (table). Multivariate analysis (Cox proportional hazard model) included the 2 significant prognostic factors of univariate analysis and showed that serum CEA level was independent prognostic factor for OS (figure).

Conclusion

Serum CEA level was identified as important prognostic factors for OS in advanced pancreatic cancer with elderly patients. These findings may also facilitate pretreatment prediction of OS and can be used for selecting elderly patients for treatment.